These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8903661)
61. [Clinical study of arterial rigidity. Part II. Remodeling of vessels in arterial hypertension and metabolic syndrome. possibilities of correction with drugs]. Oleĭnikov VE; Matrosova IB Kardiologiia; 2009; 49(12):51-7. PubMed ID: 20038283 [TBL] [Abstract][Full Text] [Related]
62. The L-arginine-nitric oxide pathway in hypertension. Kelm M Curr Hypertens Rep; 2003 Feb; 5(1):80-6. PubMed ID: 12530940 [TBL] [Abstract][Full Text] [Related]
63. Can antihypertensive treatment reverse large-artery stiffening? Safar ME Curr Hypertens Rep; 2010 Feb; 12(1):47-51. PubMed ID: 20425158 [TBL] [Abstract][Full Text] [Related]
64. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition. Safar ME; Levy BI; London GM J Hypertens Suppl; 1992 Jul; 10(5):S51-7. PubMed ID: 1403234 [TBL] [Abstract][Full Text] [Related]
65. Vascular remodeling and antihypertensive therapy: the example of cicletanine. Chabrier PE; Esanu A; Braquet P J Cardiovasc Pharmacol; 1993; 21 Suppl 1():S50-3. PubMed ID: 7681131 [TBL] [Abstract][Full Text] [Related]
66. Effects of noradrenaline on consecutive vascular segments at low or normal calcium concentrations in control and spontaneously hypertensive rats. Folkow B; Hallbäck M; Jones JV; Sutter M Clin Sci Mol Med Suppl; 1976 Dec; 3():53s-55s. PubMed ID: 1071675 [TBL] [Abstract][Full Text] [Related]
67. Regression of structural alterations of hypertension with calcium antagonists--vascular hypertrophy. Hansson L J Hypertens Suppl; 1987 Dec; 5(4):S71-4. PubMed ID: 2894420 [TBL] [Abstract][Full Text] [Related]
68. Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view. Campbell RW Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():525-8. PubMed ID: 8562469 [TBL] [Abstract][Full Text] [Related]
69. Effects on ACE inhibitor therapy on derived central arterial waveforms in hypertension. O'Rourke MF Am J Hypertens; 2002 May; 15(5):476-7; author reply 477. PubMed ID: 12022254 [No Abstract] [Full Text] [Related]
70. Future directions in the use of calcium antagonists. Fleckenstein A; Fleckenstein-Grün G; Frey M; Zorn J Am J Cardiol; 1987 Jan; 59(3):177B-187B. PubMed ID: 2433933 [TBL] [Abstract][Full Text] [Related]
71. Reversal of structural changes in hypertensive--a major prospect for the future? Rosendorff C S Afr Med J; 1991 Aug; 80(3):121-2. PubMed ID: 1862442 [No Abstract] [Full Text] [Related]
75. The ideal agent for perioperative hypertension and potential cytoprotective effects. Levy JH Acta Anaesthesiol Scand Suppl; 1993; 99():20-5. PubMed ID: 8480502 [TBL] [Abstract][Full Text] [Related]
76. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Heagerty AM; Bund SJ; Aalkjaer C Lancet; 1988 Nov; 2(8622):1209-12. PubMed ID: 2903951 [TBL] [Abstract][Full Text] [Related]
78. [Electroarteriographic evaluation of the vascular response to the therapeutic effects of vasomotor drugs]. LI VOTI P; CATALIOTTI F Minerva Cardioangiol; 1958 Apr; 6(4):250-6. PubMed ID: 13552022 [No Abstract] [Full Text] [Related]
79. Studies on vasomotor tone in the hypertensive state. HOOBLER SW; LYONS RH Proc Annu Meet Cent Soc Clin Res U S; 1947; 20():27. PubMed ID: 20272789 [No Abstract] [Full Text] [Related]
80. Vasomotor activity of NU-1683 and other drugs upon the rat meso-appendix. KUNZE DC; BOBB JR; GREEN HD Fed Proc; 1948 Mar; 7(1 Pt 1):235. PubMed ID: 18938553 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]